Skip to search formSkip to main contentSkip to account menu

semuloparin

An ultralow-molecular-weight heparin (ULMWH) (Mw: 2000-3000 daltons)consisting of a polydisperse mixture of oligomeric heparin fragments with… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AVE 5026Panheprin

Broader (1)

Heparin, Low-Molecular-Weight
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Despite the morbidity and mortality associated with VTE in cancer patients, current clinical practice guidelines do not recommend routine thromboprophylaxis in outpatients with cancer. The relatively…
associated with VTE in cancer patients, current clinical practice guidelines do not recommend routine thromboprophylaxis in… 
2012
2012
Thromboembolieprophylaxe mit Semuloparin: SAVE-ONCO-Studie mit positiven Ergebnissen
Beinvenenthrombosen und Lungenembolien sind häufige Komplikationen bei Patienten mit fortgeschrittenen Tumorleiden und haben… 
2012
2012
Tumor und Thrombose – eine unterschätzte Gefahr: Semuloparin: Thromboembolieprophylaxe ohne erhöhtes Blutungsrisiko
Das erhöhte Thromboserisiko von Tumorpatienten lässt sich durch eine primäre Prophylaxe zuverlässig senken. Mit Semuloparin… 
2012
2012
Semuloparin helps prevent thromboembolic events in patients receiving chemotherapy.
Semuloparin, an ultra-low molecular weight heparin reduces the probability that a cancer patient undergoing chemotherapy has a… 
Review
2012
Review
2012
Thromboprophylaxis in patients receiving chemotherapy.
To the Editor: In their article on the results of the SAVE-ONCO study (ClinicalTrials.gov number, NCT00694382), which showed that… 
2011
2011
Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VIE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and…